Skip to content
Contact us
All posts

A Competitor Launched Six Months Before You. Is There Still Room in the Market?

Picture of Varsha Sundaram   Varsha Sundaram  ·  3 minute read

A Competitor Launched Six Months Before You. Is There Still Room in the Market

A six-month head start doesn't usually mean a market is closed, it usually means one specific patient segment is closed. In one ZoomRx launch tracking engagement, a specialty biotech found that its same-mechanism competitor's early traction was concentrated almost entirely in a single patient archetype, while the rest of the addressable market remained genuinely open. Aggregate market-share data couldn't show that distinction. Archetype-level tracking could.

That's not a reason to assume every later launch has room to work with, some markets really do close fast. But it's worth checking before writing off a launch as too late, because the data usually needed to tell the difference isn't hard to get; it's just not in the report most teams are already looking at.

The Question Behind the Question

A small specialty biotech was preparing to launch its first-ever brand as a second-in-class entrant, with a same-mechanism competitor already six months into the market. Early signals were encouraging, syndicated data and advisory board feedback suggested the category was still forming and the competitor hadn't fully defined it. But one important question sat unresolved: was the competitor gaining broadly across the patient population, or was its early traction concentrated in one archetype that could materially change the new brand's own peak-share assumptions? The team needed an answer before field strategy and launch messaging locked in.

What the Aggregate Numbers Showed, and Didn't

At a glance, usage looked broadly consistent across the five patient segments the team was tracking, ranging from about 32% to 43% overall. Nothing in that view suggested any one group was materially different from the others. If the team had stopped there, the reasonable conclusion would have been that the competitor's presence was roughly even across the whole eligible population, a genuinely hard market to find room in.

What Archetype-Level Tracking Found Instead

ZoomRx layered three data sources against the same patient segments: a continuous specialist panel tracking awareness and prescribing intent, a patient chart module capturing real prescribing decisions by archetype, and a competitive promotion tracker capturing what the competitor's reps were actually saying in the field. Together, they showed something the aggregate view had missed.

In one specific patient subgroup, competitive consideration jumped sharply, physicians who considered the competitor product went on to prescribe it roughly 70% of the time, versus closer to 35–56% in the other four segments. And in that same subgroup, the competitor's rep reach was the lowest of any segment tracked, only about 20% of treating physicians, compared with over 90% in another. The competitor wasn't winning that segment through promotion. They'd already won it on clinical fit alone, without needing to fight for it.

The competitor owned one post-failure archetype. Adjacent segments were genuinely open. — ZoomRx Launch Tracking, Scenario 1

Why This Changed the Plan

Once the team could see the traction was concentrated rather than even, they stopped treating the whole market as contested. Field-force training was re-cut around the patient archetypes that remained genuinely open, and launch messaging was adjusted about six weeks before launch, while there was still time for it to matter.

The Question Worth Asking Before You Assume It's Too Late

A head start compounds inside the specific segment a competitor has actually locked down, it doesn't automatically extend across the whole addressable population. Before assuming a market is closed, the more useful question is: which patient archetype is the incumbent actually winning, versus just present in? Aggregate share numbers and rep-reach data on their own won't answer that. Layered against the same patient segments, together, they usually will.

This scenario is one of five blind spots the full whitepaper walks through. For the complete set, download it below.

DOWNLOAD THE FULL WHITEPAPER

If you're trying to work out whether your own market has more room than the aggregate numbers suggest, ZoomRx's Launch Excellence and ATU Brand Tracking pages walk through how archetype-level tracking works in practice.

 

Frequently Asked Questions 

Is it too late to launch a pharma brand after a competitor has been on the market for six months?

Not necessarily. A competitor's head start often concentrates in one specific patient segment rather than spreading evenly across the whole market, in one tracked case, a competitor had captured 70% of considered prescriptions in a single patient archetype while leaving adjacent segments largely untouched. Whether a later launch has room depends on where that concentration sits, not just how long the competitor has been live.  

How can you tell if a competitor's market share is concentrated in one patient segment?

Aggregate usage or share data alone usually won't show this, it can look evenly distributed even when it isn't. Tracking prescribing behavior and competitive consideration by specific patient archetype, rather than across the whole population, is what reveals whether a competitor's traction is broad or concentrated.

Why might a competitor have low rep reach in the patient segment they're winning most?

When a competitor's advantage in a segment comes from clinical fit rather than promotion - for example, being the only option after a prior therapy has failed, physicians there don't need heavy field detailing to prescribe it. Low rep reach paired with high prescribing share is a signal the segment is won on clinical grounds, not promotional pressure, which matters for how a new entrant should plan to compete there.

What data do you need to find an open patient segment after a competitor launch?

Finding it typically requires three things layered against the same patient segments: specialist-level awareness and intent data, patient-level prescribing data by archetype, and a read on what the competitor's field force is actually promoting. Any one of these alone tends to understate or mask where a market is genuinely still open.

How far in advance can archetype-level tracking change a launch plan?

In one tracked case, this kind of segment-level read let a team retrain its field force and adjust launch messaging about six weeks before launch, early enough for the changes to actually influence the plan rather than just explain results after the fact.